🔗 Share this article

While the US proceeds with unprecedented revisions to its vaccine schedules, a particular individual appears in a surprising turn: Dr. Tracy Beth Høeg, a Danish American sports medicine doctor and public health researcher who rose to prominence by expressing skepticism about coronavirus shots throughout the global health crisis and has focused upon alleged deaths following COVID-19 immunization in her recent tenure at the FDA.

Proposed Shifts to Pediatric Immunization Program

Public health authorities planned to reveal sweeping changes to the childhood vaccine schedule in December, aligning the US with Denmark’s immunization schedule, it is understood – a substantial departure that would put the US out of alignment with much of the global community with little proof for public health gain. The announcement has been postponed until the coming year.

Instead of the top vaccines chief, Dr. Høeg is scheduled to present at the gathering. She was newly appointed interim head of the FDA’s CDER, the fifth appointee to run the center this calendar year.

A Shift at the FDA

The acting appointment could signify a strengthened alliance between the drug and biologics branches as Dr. Høeg and Prasad strengthen their influence at the agency – and it signals a greater focus upon reevaluating long-standing vaccines at the FDA.

The new acting director has frequently advocated for ending specific pediatric immunization guidelines in the US in order to be more like the Danish model, a country with nationalized medicine and a number of inhabitants approximately the population of the state of Wisconsin.

In her initial public appearances, she has persisted in emphasizing on vaccination policy – usually the purview of Dr. Prasad, chief of the FDA’s CBER – as opposed to drug regulation.

Doubts Over Expertise

Dr. Høeg has no obvious track record in drug development, oversight or leadership, which has been standard for former heads of the Center for Biologics Evaluation and Research. She has served at the FDA as a top consultant to the agency head and CBER since March.

“She doesn’t seem to have any of the qualifications” for running the drug-regulation department, stated a neurologist and psychiatrist. “She lacks experience running a clinical trial. She has no expertise in running a major agency. She lacks background in industry regulation.”

Past heads of CBER would “understand regulatory frameworks and the research of drug development”, commented Dr. Janet Woodcock. “Clearly, she doesn’t have the type of experience that former directors who headed CBER have had.”

The drug center has an immense workload at the agency, Woodcock emphasized.

“The public just pays attention on the new drug program, but the generic program authorizes numerous off-brand pharmaceuticals. There’s a biosimilars division, over-the-counter program and so forth, and every single one have to be supervised,” Woodcock noted. “The responsibility you don’t keep your eye on, that is the part that I always told people is going to come back to haunt you.”

Additionally, a significant management element to the role, which oversees in excess of 5,000 staff members. “It is a massive leadership role, if you perform it correctly,” she added.

Agency Reaction and Contentious Initiatives

Regarding concerns about Høeg’s qualifications and whether this selection signifies greater collaboration among FDA leaders on immunizations, a representative said that the “inquiries are based on inaccurate assumptions”.

“This background aligns with the responsibilities of her role,” the spokesperson explained, noting the time Dr. Høeg spent guiding the agency head on “drug safety and regulatory science, including computerized risk analysis and vaccine surveillance”.

As acting director, Dr. Høeg assumes responsibility for the agency head's recently launched priority voucher program, a disputed one-day drug-approval program that reportedly concerned her predecessors. “How are these therapies being chosen for this fast-track system? Who makes the calls?” Dr. Howard questioned. “There is a lot of secrecy going on at the FDA right now.”

Broadly speaking, he said, “the agency seems to be moving towards laxer regulations of pharmaceuticals, aside from immunizations.”

Established Track Record on Immunizations

Regarding immunizations, Dr. Høeg has a more documented, if troubling, history, some experts have noted. She authored a analysis using unconfirmed volunteer-provided data to determine the rate of heart inflammation after COVID-19 vaccination. She consulted for the Florida surgeon general Joseph Ladapo, who reportedly have changed statistics to imply COVID-19 vaccines are pose a greater threat than they are.

Included in her “policy goals” for the current government included revising guidelines for new vaccines and discontinuing “unnecessary” immunizations, she remarked post-election on a online show. At the agency, Dr. Høeg has reportedly floated the idea of excluding young men from getting COVID-19 vaccinations.

“She is an all-around dogmatist who commences with her preconceived notions and tailors the evidence to retrofit the data in a highly misleading, fraudulent manner,” Howard stated.

Consolidating Power and a “Revenge Tour”

Høeg aligned with other skeptics, {like|